Online inquiry

IVTScrip™ mRNA-Human AOC1, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WK17969MR)

This product GTTS-WK17969MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the AOC1 protein. This product can be used in Enterocyte progenitor cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Human
RefSeq NM_001091.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 26
UniProt ID P19801
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human AOC1, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WK17969MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK8075MR IVTScrip™ mRNA-Human AEBP1, (Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AEBP1
GTTS-WK11472MR IVTScrip™ mRNA-Human ABHD8, (Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABHD8
GTTS-WK17878MR IVTScrip™ mRNA-Human ANGEL2, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ANGEL2
GTTS-WK26035MR IVTScrip™ mRNA-Human ATAD1, (Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ATAD1
GTTS-WK19353MR IVTScrip™ mRNA-Human Aminopeptidase-N, (Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Aminopeptidase-N
GTTS-WK21153MR IVTScrip™ mRNA-Human Aminopeptidase-N, (Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Aminopeptidase-N
GTTS-WK15392MR IVTScrip™ mRNA-Human Aldehyde Dehydrogenase 1-A1, (Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA Aldehyde Dehydrogenase 1-A1
GTTS-WK23145MR IVTScrip™ mRNA-Human APRT, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA APRT
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW